Hypothesis

Rapamycin extends lifespan by suppressing turnover of AGE‑crosslinked collagen, thereby sequestering damaged matrix and preventing release of pro‑inflammatory matricryptins. This damage‑containment strategy trades tissue compliance for organismal stability, and predicts that forced matrix degradation will abolish rapamycin’s survival benefit.

Mechanistic rationale

Aging increases lysine glycation and advanced glycation end‑product (AGE) accumulation in collagen, raising tissue stiffness and shifting the MMP/TIMP balance toward net matrix accrual (1, 2). Rapamycin activates autophagy and stress pathways without reducing existing AGE crosslinks (2) and its metabolic effects appear only in middle‑aged animals, indicating action on pre‑existing damage (3). In this context, further inhibition of mTOR‑driven MMP expression (4) lowers the already‑deficient proteolytic capacity, locking glycated collagen in place. The resulting reduction in matricryptin generation limits chronic inflammasome activation, which is a major driver of age‑related mortality.

Novel insight

We propose that the longevity signal is not a generic stress response but a specific blockade of matrix‑derived danger signals. Consequently, interventions that increase collagenolysis—such as resistance exercise, MMP‑gene overexpression, or pharmacologic MMP activators—should counteract rapamycin’s effect by liberating AGE‑rich fragments.

Testable predictions

1. In middle‑aged mice treated with rapamycin, collagen turnover rates measured by deuterated collagen labeling will be lower than in untreated controls, while total AGE content remains unchanged.
2. Genetic overexpression of MMP‑2 in the rapamycin‑treated cohort will increase soluble collagen fragments in plasma and shorten lifespan relative to rapamycin‑only animals.
3. Administration of a synthetic AGE‑collagen peptide that mimics matricryptin activity will rescue the shortened lifespan of MMP‑overexpressing, rapamycin‑treated mice, confirming that fragment release drives the phenotype.
4. Histological analysis will show increased collagen cross‑link density and unchanged autophagic flux in rapamycin‑treated tissues, confirming that the matrix is stabilized rather than cleared.

Experimental design (falsifiable)

• Use C57BL/6 mice, start rapamycin (14 ppm diet) at 12 months of age.
• Cohorts: (a) control, (b) rapamycin, (c) rapamycin + MMP‑2 transgene (inducible), (d) rapamycin + MMP‑2 transgene + matricryptin neutralizing antibody.
• Measure survival, plasma collagen‑derived peptide levels (mass spectrometry), tissue hydroxyproline, AGE immunostaining, and MMP activity assays.
• If rapamycin’s lifespan extension persists despite elevated MMP activity and increased matricryptin levels, the hypothesis is falsified. Conversely, a loss of benefit when matrix degradation is enhanced supports the damage‑containment model.

Implications

If validated, the framework shifts the goal from matrix repair to controlled matrix sequestration, suggesting that geroprotectors should be evaluated for their impact on matricryptin release rather than on autophagy alone.